Refine by
Colitis Equipment & Supplies
277 equipment items found
Manufactured by:Adiso Therapeutics based inConcord, MASSACHUSETTS (USA)
ADS024 is an oral single strain live biotherapeutic product (SS-LBP). A naturally occurring live biotherapeutic product, ADS024 modulates inflammation as a single strain multimodal LBP and has been shown to reduce neutrophil trafficking through the colonic epithelium. ADS024 is manufactured from a pure, clonal bacterial cell bank, yielding a standardized lyophilized drug product ...
Manufactured by:MV BioTherapeutics SA based inBellinzona, SWITZERLAND
SNP-apyrase for oral use in the treatment of IBD • Lead compound, MV010, has shown animal PoC in a murine model of ulcerative colitis. • Abrogation of the pro-inflammatory function of extracellular ATP in the intestine without systemic immune suppression. • Amplification of secretory IgA production in Peyer's patches and gut-associated lymphoid tissue (GALT), ensuring high ...
Manufactured by:Benevolent based inLondon, UNITED KINGDOM
Better target discovery and compound design in Ulcerative Colitis. What is UC?: Ulcerative colitis (UC) is a chronic, lifelong disease that causes inflammation and ulceration of the inner lining of the colon and rectum, accompanied by debilitating symptoms. Our work: There is no cure for UC, current treatments have side effects and don’t work on all ...
Manufactured by:Adiso Therapeutics based inConcord, MASSACHUSETTS (USA)
ADS051 is an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis. ADS051 blocks MRP2 release of HXA3 gradient, while also blocking FPR1 activation of neutrophils within the colonic epithelium. Unlike currently available therapies, this addresses neutrophil-mediated tissue damage, a hallmark of UC ...
by:Abivax based inParis, FRANCE
ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in preclinical trials and in Phase 2a and Phase 2b induction trials to treat ulcerative colitis (UC). Patients who completed the induction studies had the option to roll over into the respective open-label extension ...
Manufactured by:Lumen Bioscience, Inc. based inSeattle, WASHINGTON (USA)
Traditionally considered a hospital-acquired infection, C. difficile is increasingly arising in the broader community. For this reason, the shelf-stable, orally delivered format of Lumen’s product is an important addition to the tool kit for treating and preventing this disease. Long-term consequences can include chronic diarrhea, severe intestinal inflammation, surgical resection, and ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-287 is an investigational, oral, biologically-derived microbiome therapeutic for the treatment of ulcerative colitis (UC). SER-287 is a consortium of multiple bacterial spores manufactured by fractionating and purifying targeted bacteria from stool of healthy human donors. SER-287 has been granted Fast Track designation and Orphan Drug designation by the FDA. A completed ...
Manufactured by:Entero Therapeutics, Inc. based inBoca Raton, FLORIDA (USA)
FW-ICI-AC is a niclosamide-based, oral, small molecule anti-inflammatory inhibitor therapy for the treatment of immune checkpoint inhibitor (ICI)-associated colitis and diarrhea in metastatic cancer patients. The PASSPORT clinical trial, a Phase 2a study to determine the safety and potential efficacy of niclosamide in the treatment of ICI-AC, received FDA IND clearance in Q4 ...
Manufactured by:Seres Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
SER-301 is an investigational, oral, rationally-designed, fermented microbiome therapeutic for the treatment of mild-to-moderate ulcerative colitis (UC). SER-301 is a consortium of multiple bacterial strains that is manufactured by fermenting each strain individually and then combining to form drug product. ...
Manufactured by:Galapagos NV based inMechelen, BELGIUM
Filgotinib, a preferential JAK1 inhibitor, is marketed as Jyseleca in the European Union (incl. Norway), Great Britain, and Japan for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Mirikizumab (Anti-IL-23) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23. Mirikizumab can be used for research on ulcerative colitis. MW: 144.26 ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Anrukinzumab (Anti-IL-13) is a humanized monoclonal antibody targeting IL-13. It reduces lung inflammation and can be used in studies of ulcerative colitis (UC) as well as asthma. MW :150 ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Visilizumab (Anti-CD3) is a humanized, non-Fc receptor (FcR)-binding IgG2 monoclonal antibody (MoAb) directed against CD3 with potential immunosuppressive activity. Visilizumab has the potential to be used for ulcerative colitis and Crohn's disease research. MW : 144.62 ...
Manufactured by:NANOLEK LLC based inMoscow, RUSSIA
Anti-tumor necrosis factor-alpha monoclonalantibody. Effective in rheumathoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, ankylosing ...
Manufactured by:Ferring Pharmaceuticals based inSaint-Prex, SWITZERLAND
CORTIMENT®MMX® (budesonide)* is indicated in adults for induction of remission in patients with active mild-to-moderate active ulcerative colitis where 5-ASA (aminosalicylate) treatment is not ...
Manufactured by:Galapagos NV based inMechelen, BELGIUM
In the course of 2013, GSK initiated Phase 2 studies with GSK2586184 (formerly GLPG0778) in systemic lupus erythematosus, chronic plaque psoriasis, and ulcerative colitis. In February 2014, GSK stopped the lupus study due to a lack of effect and put the ulcerative colitis study on hold. In April ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
It targets the key IL-23 and inhibits the production of cytokines lying downstream of the IL-23 signaling pathway and can be used for reatment of psoriatic arthritis, Crohn's disease, and ulcerative colitis. MW : 145.5 ...
Manufactured by:Bausch Health Companies Inc. based inLaval, QUEBEC (CANADA)
For over 30 years, Salix has licensed, developed and marketed innovative products to treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea, traveler’s diarrhea, opioid-induced constipation and ulcerative colitis, among many others. ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
P-2281 is a mTOR inhibitor with anticancer and anti-inflammatory efficacies. P-2281 suppresses dextran sulfate sodium (DSS)-induced colitis by inhibiting T cell function and is efficacious in a murine model of human ...